9 Overstated
Up to menopause women are protected against cardiometabolic conditions and fatty liver, but after menopause disease rates accelerate and catch up to men around age 60.
"as um up to menopause a woman is protected against all kinds of disease states, you know, including all cardiometabolic states, fatty liver, just the list goes on and on. And then as you go through menopause, a woman actually catches back up to a man, and so the rate actually accelerates faster than a man as as you lose estrogen and catches back up, you know, close to around 60." (said at 0:04:15)
The speaker accurately describes the sex-specific trajectory of cardiometabolic risk and nonalcoholic fatty liver disease (NAFLD): premenopausal women exhibit relative protection compared to men due to estrogen-mediated effects on fat partitioning and vascular health, followed by accelerated accumulation of visceral adiposity and metabolic risk post-menopause that narrows the gap with men around age 60. However, claiming that premenopausal women are protected against 'all kinds of disease states' and 'all cardiometabolic states' overstates the level of protection, as premenopausal women can and do develop cardiometabolic disorders and liver disease.
Sulforaphane activates the NRF2 pathway, turning on phase II detoxification and promoting the expression of 200 antioxidant genes for up to 72 hours.
"sulforaphane is the best natural molecule at turning on the NRF2 pathway. And that's important because that's responsible for phase two detoxification. ... turns on 200 different genes that express and promote 200 different antioxidants. And they it stays on for 72 hours." (said at 0:09:16)
Sulforaphane (SFN) is well established in preclinical and biochemical studies as a potent activator of the Keap1/Nrf2/ARE signaling pathway, which upregulates downstream cytoprotective, phase II detoxification enzymes and endogenous antioxidant proteins. However, the speaker overstates and simplifies these findings in several ways. While the Nrf2 transcriptional network controls hundreds of cytoprotective genes (estimates often range around 200+ genes in transcriptomic profiling), these encode various phase II enzymes, glutathione-synthesis proteins, and transporters, rather than directly expressing '200 different antioxidants' that remain continuously active for a fixed 72-hour period in vivo across tissues. Furthermore, calling it the single 'best natural molecule' is an absolute ranking unsupported by clinical consensus, and randomized clinical trials in humans (such as in atopic asthmatics consuming broccoli sprouts) have demonstrated that oral intake does not consistently induce cytoprotective antioxidant gene expression in target tissues or reduce markers of oxidative stress.
- partial: Induction of phase 2 antioxidant enzymes by broccoli sulforaphane: perspectives in maintai… (Frontiers in genetics 2012) · cited 109x in the literature
"The ITC sulforaphane, which is derived from glucoraphanin, has garnered particular interest as an indirect antioxidant due to its extraordinary ability to induce expression of several enzymes via the KEAP1/Nrf2/ARE pathway. Nrf2/ARE gene products are typically characterized as Phase II detoxification enzymes and/or antioxidant (AO) enzymes." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: A Randomized Controlled Trial of the Effect of Broccoli Sprouts on Antioxidant Gene Expres… (The journal of allergy and clinical immunology. In practice 2016) · cited 54x in the literature
"BS ingestion for 3 consecutive days did not reduce FENO, despite resulting in a marked increase in serum SFN concentrations (21 vs 22 parts per billion, P = .76). Furthermore, BS consumption did not induce cytoprotective antioxidant genes in either PBMCs or nasal epithelial cells, reduce OS and inflammatory markers, or improve lung function." (abstract, results, passage verified)
pubmedfull study (doi)
Patients taking standard starting and high doses of GLP-1 receptor agonists experience a 45% to 50% increase in SIBO (Small Intestinal Bacterial Overgrowth).
"There's like a 45 to 50% increase in SIBO in patients who are taking standard doses." (said at 0:27:50)
A large retrospective multicenter cohort study (TriNetX database, 216,173 propensity score-matched pairs) found that GLP-1 receptor agonist and dual GLP-1/GIP receptor agonist therapy was associated with an increased hazard of short-term diagnostically confirmed small intestinal bacterial overgrowth (SIBO) compared to other second-line type 2 diabetes medications (HR 2.14, 95% CI 1.13–4.07). However, the absolute incidence of SIBO in this population was extremely low (0.177 per 1,000 patient-years vs. 0.083 per 1,000 patient-years). No published evidence shows a 45% to 50% increase in SIBO; this figure likely conflates overall gastrointestinal adverse event rates commonly reported with GLP-1 agonists (such as nausea, diarrhea, and constipation affecting 40%–50% of clinical trial participants) with SIBO risk.
Direct antioxidants like vitamin A, vitamin C, and vitamin E have been shown to block the exercise stimulus that leads to strength gains.
"So, all the all the ones that have been shown to block exercise um uh were that you know, the stimulus that makes you get stronger are like vitamin E, vitamin A, vitamin C, you know, the direct antioxidants." (said at 0:37:20)
While high-dose antioxidant supplementation (particularly vitamins C and E) has been shown in some studies to dampen acute redox-sensitive intracellular signaling pathways and selectively attenuate certain muscular hypertrophy metrics, meta-analyses and randomized controlled trials show that they do not consistently block or attenuate gains in muscle strength. A 2020 systematic review and meta-analysis of randomized controlled trials (PMID 31851538) found no significant negative effect of vitamin C and/or E supplementation on muscle strength or lean mass gains following resistance training. In individual trials, such as Bjørnsen et al. (PMID 26129928), maximal strength (1RM) improved significantly and similarly in both antioxidant and placebo groups despite minor differences in lean mass gains. Furthermore, evidence specifically demonstrating that vitamin A blocks strength adaptations is lacking.
- partial: Vitamin C and E supplementation blunts increases in total lean body mass in elderly men af… (Scandinavian journal of medicine & science in sports 2016) · cited 103x in the literature
"Increases of lean mass in trunk and arms, and muscle thickness of elbow flexors, did not differ significantly between groups. With no group differences, 1RM improved in the range of 15-21% (P < 0.001). In conclusion, high-dosage vitamin C and E supplementation blunted certain muscular adaptations to strength training in elderly men." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: The effects of vitamin C and E on exercise-induced physiological adaptations: a systematic… (Critical reviews in food science and nutrition 2020) · cited 43x in the literature
"There were also no effects of these supplements on lean mass and muscle strength following RT (SMD -0.07, 95% CI: -0.36 to 0.23, P = 0.67) and (SMD -0.15, 95% CI: -0.16 to 0.46, P = 0.35), respectively... These findings suggest that vitamin C and/or E does not inhibit exercise-induced changes in physiological function." (abstract, results, passage verified)
pubmedfull study (doi)
Sulforaphane exerts protective antimicrobial effects against Helicobacter pylori and small intestinal bacterial overgrowth (SIBO).
"it's actually protective for bacteria in your stomach like H H. pylori. It's protective of SIBO. Um if you get high doses released right into your um small intestines, it would be protective." (said at 0:47:48)
The speaker overstates the evidence by asserting that sulforaphane is protective against small intestinal bacterial overgrowth (SIBO) and that high doses released into the small intestine are protective, while claiming antimicrobial protection against Helicobacter pylori.
For Helicobacter pylori, in vitro and preclinical studies show direct antibacterial activity, and clinical trials demonstrate that sulforaphane-rich broccoli sprout consumption reduces H. pylori colonization markers and attenuates gastric inflammation (PMID 19349290, PMID 39741515). However, human clinical trials show that sulforaphane does not reliably eradicate H. pylori when given alone (PMID 25287166) or improve eradication rates when added to standard clarithromycin-based triple therapy (PMID 31830776).
For SIBO, there is no published clinical or preclinical evidence evaluating sulforaphane as a treatment or protective agent against SIBO. A systematic review of sulforaphane's antibacterial effects notes protection against aspirin-induced small intestinal damage in preclinical models, but does not identify evidence for SIBO (PMID 40553560). No published record matching sulforaphane for SIBO was located.
- supports: Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in … (Cancer prevention research (Philadelphia, Pa.) 2009) · cited 276x in the literature
"Intervention with broccoli sprouts, but not with placebo, decreased the levels of urease measured by the urea breath test and H. pylori stool antigen (both biomarkers of H. pylori colonization) and serum pepsinogens I and II (biomarkers of gastric inflammation)." (abstract, results, passage verified)
pubmedfull study (doi) - partial: The Effects of Broccoli Sprout Extract Containing Sulforaphane on Lipid Peroxidation and H… (Gut and liver 2015) · cited 53x in the literature
"BSES treatment did not significantly affect the UBT values or ammonia concentration in group A (p=0.634 and p=0.505, respectively). BSES treatment did significantly reduce mucosal MDA concentrations in group A (p<0.05) and group C (p<0.001)" (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with … (The Korean journal of internal medicine 2020) · cited 30x in the literature
"Probiotic or sulforaphane with triple therapy for H. pylori infection neither increased the eradication rate nor reduced the occurrence of adverse events." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: Can a diet rich in Brassicaceae help control Helicobacter pylori infection? A systematic r… (Frontiers in medicine 2024) · cited 3x in the literature
"Available evidence indicates that Brassicaceae consumption exhibits the potential to reduce Hp colonization but achieving complete eradication of the pathogen remains challenging." (abstract, results, passage verified)
pubmedfull study (doi) - context: Antibacterial effects of sulforaphane - A phytonutrient derived from broccoli as promising… (European journal of microbiology & immunology 2025) · cited 5x in the literature
"SFN i.) exerted antimicrobial effects against a variety of Gram-positive and Gram-negative bacteria; ii.) counteracted distinct virulence factors such as biofilm formation and toxin production (e.g. Shiga toxin); iii.) enhanced antibacterial immune cell responses mounting in anti-oxidant and anti-inflammatory actions thereby supporting bacterial killing and dampening inflammatory cell and tissue damage; iv.) prevented from aspirin-induced small intestinal cell injury; and v.) alleviated Helicobacter pylori-induced gastritis." (abstract, results, passage verified)
pubmedfull study (doi)
Sulforaphane directly conjugates and inhibits STAT3 dimerization.
"I was going to start talking about STAT3. That's a new thing that that I found out it directly conjugates and and inhibits STAT3, which is in the center of inflammation in in tons of ways. And I was looking for, you know, a supplement to try and um work on, you know, the dimerization of STAT3. And it turns out sulforaphane is the best at that." (said at 0:56:25)
Preclinical cell culture studies show that sulforaphane can suppress STAT3 activation and phosphorylation (typically secondary to upstream kinases such as JAK2/Src, ROS modulation, or interactions with regulatory partners like PKM2). However, published literature does not demonstrate that sulforaphane directly conjugates to STAT3 to block its dimerization, nor is there comparative clinical evidence establishing sulforaphane as the 'best' supplement for targeting STAT3 dimerization. All existing evidence for sulforaphane's effects on STAT3 signaling is limited to preliminary in vitro and animal models.
The majority of the conversion of glucoraphanin to sulforaphane is performed by gut bacteria in the colon.
"the precursor, majority of the conversion happens by bacteria in your colon" (said at 0:47:48)
The claim that the majority of glucoraphanin conversion to sulforaphane occurs via gut bacteria in the colon is overstated. In fresh cruciferous vegetables, the plant enzyme myrosinase rapidly converts glucoraphanin to sulforaphane upon chewing and upper gastrointestinal digestion, providing approximately 3- to 10-fold higher bioavailability than microbial conversion. Mammalian host cells lack myrosinase-like activity, so when plant myrosinase is inactivated by cooking, blanching, or in isolated glucoraphanin supplements, conversion does rely on colonic microbiota; however, microbial conversion is relatively inefficient (bioavailability typically around 10–20%), meaning most ingested glucoraphanin remains unconverted or is metabolized into other compounds.
- partial: Isothiocyanate concentrations and interconversion of sulforaphane to erucin in human subje… (Molecular nutrition & food research 2012) · cited 127x in the literature
"Sulforaphane bioavailability was about tenfold higher for the soups made from fresh compared to frozen broccoli, and the reduction was shown to be due to destruction of myrosinase activity by the commercial blanching-freezing process... Sulforaphane was converted to erucin and excreted in urine, and it was shown that human colonic flora were capable of this conversion." (abstract, results, passage verified)
pubmedfull study (doi) - context: Glucoraphanin conversion into sulforaphane and related compounds by gut microbiota. (Frontiers in physiology 2025) · cited 31x in the literature
"Sulforaphane is formed by the hydrolysis of glucoraphanin by a plant enzyme called myrosinase, which is inactivated in the stomach of mammals. Since the latter do not have enzymes possessing myrosinase-like activity, glucoraphanin can be metabolized by the gut microbiota, to sulforaphane, sulforaphane-nitrile, glucoerucin, erucin, and erucin-nitrile." (abstract, background, passage verified)
pubmedfull study (doi) - partial: Exogenous myrosinase from mustard seed increases bioavailability of sulforaphane from a gl… (Scientific reports 2026) · cited 3x in the literature
"Inactive glucoraphanin (GR) in broccoli is converted to the antioxidant, anti-inflammatory, and anti-bacterial sulforaphane (SF) by cruciferous vegetable enzyme myrosinase (Myr), or similar enzymes from specific gut bacteria; both sources have variable efficiency. The effects of exogenous Myr on the conversion efficiency of GR to SF was compared to gut microbial Myr-like activity. In a randomized, double-blind, crossover study, sixteen subjects (9 F: 7 M) received a single oral dose of GR in broccoli seed extract with Myr-containing mustard seed powder, or broccoli seed extract alone, both with ascorbic acid. GR + Myr, on average, doubled the bioavailability of SF (39.8 ± 3.1%) compared to GR alone (18.6 ± 3.1%)" (abstract, results, passage verified)
pubmedfull study (doi)
Sulforaphane activates the Nrf2 pathway in skin cells, helping to treat acne.
"if people with acne, it can be hard to to get rid of that and and so we have um you know, testimonials of people, you know, within several weeks um seeing a noticeable difference if not a complete, you know, reversal. And that's because of the NRF2 pathway and it's it gets to to each each skin cell." (said at 1:12:13)
Sulforaphane is known to activate the antioxidant and anti-inflammatory Keap1/Nrf2 signaling pathway in skin cells. However, claims that Nrf2 activation by sulforaphane leads to clinical reversal or treatment of active acne vulgaris rely primarily on mechanistic rationale and anecdotal reports; robust clinical trial evidence validating sulforaphane as an effective treatment for active acne in humans is currently lacking.
A large number of the side effects and symptoms of menopause are caused by the loss of estrogen receptor beta (ERβ) activation.
"a large number of the side effects from menopause are are because of the loss of estrogen receptor beta activation." (said at 1:20:23)
While estrogen receptor beta (ERβ) is actively researched as a target for selective therapies to alleviate menopausal symptoms (such as hot flashes and memory dysfunction) without the cancer risks driven by estrogen receptor alpha (ERα) activation, claiming that a "large number of the side effects from menopause are because of the loss of estrogen receptor beta activation" overstates the evidence. Both ERα and ERβ mediate estrogenic signaling, and animal models indicate that activation of either receptor (or predominantly ERα in classical pathways) can regulate thermoregulation and other physiological symptoms. Selective ERβ agonists (e.g., MF101/Menerba, EGX358) are being developed for therapeutic symptom relief, but menopausal symptoms stem broadly from systemic loss of circulating 17β-estradiol acting across both ERα and ERβ, as well as non-genomic estrogen pathways.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.